Swedish Electric Utilities Stock News

OM:VERT B
OM:VERT BSoftware

Vertiseit (OM:VERT B) Margin Compression Challenges Bullish Growth Narratives After FY 2025 Results

Vertiseit (OM:VERT B) has wrapped up FY 2025 with fourth quarter revenue of SEK186.8 million, basic EPS of SEK0.22 and net income of SEK6.7 million, giving investors a fresh read on both growth and profitability. Over recent periods, the company has seen quarterly revenue move between SEK150.7 million and SEK202.8 million, while basic EPS has ranged from a loss of SEK0.56 to a profit of SEK0.48, setting a wide but clear context for how FY 2025 played out on the income line. With trailing 12...
OM:YUBICO
OM:YUBICOSoftware

Yubico (OM:YUBICO) Net Margin Compression Challenges Bullish Growth Narratives

Yubico (OM:YUBICO) FY 2025 earnings snapshot Yubico (OM:YUBICO) has wrapped up FY 2025 with Q4 revenue of 548.3 million SEK and basic EPS of 0.04 SEK, setting the tone for a year where trailing 12 month revenue came in at 2.2 billion SEK and basic EPS was 1.49 SEK. The company has seen quarterly revenue move between 499.1 million SEK and 623.1 million SEK over the past year, with basic EPS ranging from 0.04 SEK to 0.74 SEK. Trailing 12 month EPS and net income have tracked alongside 12 month...
OM:VSURE
OM:VSURECommercial Services

Verisure (OM:VSURE) Q4 Loss Worsens To €121.3m Challenging Bullish Profitability Narratives

Verisure (OM:VSURE) FY 2025 Earnings Snapshot Verisure (OM:VSURE) has wrapped up FY 2025 with fourth quarter revenue of €964.7 million and a basic EPS loss of €0.12, while trailing 12 month figures show revenue of about €3.7 billion and a basic EPS loss of €0.30. Over the past year, the company has seen revenue move from €870.2 million in Q4 2024 to €964.7 million in Q4 2025, while quarterly EPS stayed in loss making territory, shifting from a €0.07 loss per share in Q4 2024 to a €0.12 loss...
OM:EQT
OM:EQTCapital Markets

Is There Now An Opportunity In EQT (OM:EQT) After The Recent 30 Day Pullback

If you are looking at EQT and wondering whether the current share price still offers value, this article will walk you through what the numbers actually say about the stock. The share price last closed at SEK 290.30, with returns of 2.0% over 7 days, a 19.4% decline over 30 days, and returns of 20.7% over 3 years and 21.8% over 5 years that give useful longer term context. Recent coverage of EQT has focused on how the stock's shorter term pullback sits against its longer term record. This...
OM:CAMX
OM:CAMXPharmaceuticals

Why Camurus (OM:CAMX) Is Down 24.8% After Lifting 2026 Guidance and Showcasing Oxyesa Progress

Camurus AB reported its fourth-quarter and full-year 2025 results, with full-year sales rising to SEK 2,265.38 million and net income to SEK 735.57 million, while issuing 2026 guidance for revenues of SEK 2.60–2.90 billion and operating result of SEK 0.90–1.20 billion. Alongside these results, Camurus highlighted 2025 milestones including EU and UK approvals for Oxyesa in acromegaly and progress in long-acting metabolic therapies, underlining how its product pipeline and regulatory traction...
OM:EMBRAC B
OM:EMBRAC BEntertainment

Embracer Group (OM:EMBRAC B) Valuation Check After Volatile Share Price Performance

What recent performance says about Embracer Group (OM:EMBRAC B) Embracer Group (OM:EMBRAC B) has seen its share price move sharply in different directions, with a 19% gain over the past week and a 38% decline over the past 3 months. This places recent momentum in contrast with a weaker medium term trend. See our latest analysis for Embracer Group. At a share price of SEK54.47, Embracer Group’s sharp 18.7% 7 day share price return comes after a weaker stretch, with the 1 year total shareholder...
OM:VIMIAN
OM:VIMIANMedical Equipment

Global Stocks Trading Below Estimated Value In February 2026

As global markets navigate a period of mixed performance, with technology stocks facing challenges and value-oriented segments gaining traction, investors are keenly observing the shifts in economic indicators such as cooling U.S. labor data and fluctuating manufacturing activity. In this context, identifying undervalued stocks can be particularly appealing as they may offer potential opportunities for growth amidst the broader market volatility and sector rotations.
OM:ERIC B
OM:ERIC BCommunications

Is Ericsson (OM:ERIC B) Fairly Priced After Mixed Recent Share Price Performance?

If you are wondering whether Telefonaktiebolaget LM Ericsson’s current share price fairly reflects its potential, you are not alone. Many investors are asking the same question before making their next move. The stock last closed at SEK 97.2, with returns of a 2.3% decline over 7 days, 11.7% over 30 days, 10.1% year to date, 18.1% over 1 year, 81.0% over 3 years and 5.8% over 5 years. This gives investors plenty to think about in terms of changing sentiment and risk. Recent news coverage...
OM:SINCH
OM:SINCHSoftware

Sinch (OM:SINCH) Valuation Check As Lovable Partnership Highlights Role In AI Communications

What the Lovable partnership could mean for Sinch Sinch (OM:SINCH) has just announced a partnership with Lovable, integrating its communications tools into the Lovable Cloud to support AI-built applications and production workloads across email, messaging, and voice. The collaboration starts with Sinch's Mailgun platform for email and could broaden into wider omnichannel services as Lovable users move from early prototypes to live customer facing products. See our latest analysis for...
OM:IVSO
OM:IVSOAerospace & Defense

3 European Stocks Estimated To Be Up To 49.8% Below Intrinsic Value

As the European markets continue to show resilience amid global volatility, optimism about the eurozone economy has supported investor sentiment, with major indices like Germany's DAX and France's CAC 40 posting gains. In this environment of cautious optimism and stable interest rates from the European Central Bank, identifying undervalued stocks becomes crucial for investors looking to capitalize on potential market opportunities.
OM:HNSA
OM:HNSABiotechs

Hansa Biopharma (OM:HNSA) Heavy SEK 529 Million TTM Losses Test Bullish Turnaround Narrative

Hansa Biopharma (OM:HNSA) has reported full year 2025 results with fourth quarter revenue of SEK 76.0 million and a basic EPS loss of SEK 1.62, alongside a trailing twelve month EPS loss of SEK 6.52 on revenue of SEK 222.3 million. The company has seen quarterly revenue move between SEK 30.8 million and SEK 76.0 million across 2025, while quarterly basic EPS stayed in loss-making territory, ranging from SEK 0.55 to SEK 2.53 per share. For investors, the latest print keeps the focus squarely...
OM:CAMX
OM:CAMXPharmaceuticals

Assessing Camurus (OM:CAMX) Valuation After New 2026 Growth Guidance And Portfolio Progress

Why Camurus’ new 2026 guidance matters for shareholders Camurus (OM:CAMX) has set fresh 2026 guidance, flagging expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b, alongside several portfolio milestones. See our latest analysis for Camurus. Camurus’ new 2026 guidance follows a 9.5% year to date share price return and a 14.2% total shareholder return over the past year, which builds on a very large 3 year total shareholder return of about 19x. This...
OM:SKA B
OM:SKA BConstruction

Skanska (OM:SKA B) Valuation Check After New US And UK Infrastructure Contract Wins

Skanska (OM:SKA B) has been busy adding new work, with fresh contracts in US transport and education, and UK offices that feed directly into its order book and future earnings pipeline. See our latest analysis for Skanska. At a latest share price of SEK266.6, Skanska has seen a 1-day share price return of 0.91% and a 7-day share price return decline of 3.93%, while a 90-day share price return of 7.72% and a 1-year total shareholder return of 8.10% suggest momentum that lines up with a steady...